376
Background:
Antibody-drug conjugates (ADCs) have transformed treatment of solid tumors; however, payload-driven toxicities may affect symptom burden, treatment continuity, and outcomes. Clinical trials are often underpowered to detect delayed or multisystem adverse events and may not reflect real-world popu...
Z. Sarfraz, Tanay Venkat Malla, Ayush Patel et al.· JCO Oncology Practice· 0 citations
This review summarizes the current biologic and clinical framework of BM, including molecular divergence from the primary tumor, the evolution of prognostic models, and the growing role of brain-specific risk stratification in treatment planning.
Z. Sarfraz, R. Kotecha, Arun Maharaj et al.· Neurotherapeutics· 1 citation
In patients with recurrent BM, intracranial brachytherapy is associated with high rates of local control, supporting its role as a focal salvage strategy in carefully selected patients and underscores the need for prospective studies to better define patient selection and optimize integration with novel systemic therap...
Ruchit P. Jain, Namita Ruhela, K. Qidwai et al.· Neuro-Oncology Advances· 0 citations
In this prospective registry, resection followed by GammaTile brachytherapy achieved excellent local control, and manageable toxicity in newly diagnosed BM, supporting that GammaTile brachytherapy is a promising strategy for large or symptomatic BM.
Ruchit P. Jain, Z. Sarfraz, Mukesh Roy et al.· Neuro-Oncology Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
